IZI. V. Zhamborova

I. V. Zhamborova

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


I. V. Zhamborova has a total of 2 co-authors. Here are the top co-authors by number of shared publications:

  • G. S. Rozanova

    Pushchino Branch of the FSAEI HE Russian Biotechnological University (ROSBIOTECH), Moscow Region; FSAEI HE Mari State University, Yoshkar-Ola, 424000, Russia

    3 shared publications
  • Roman A. Bontsevich

    FSAEI HE Mari State University, Yoshkar-Ola, Russia; FSAEI HE Belgorod State National Research University, Belgorod, Russia; Kazan State Medical Academy – Branch Campus of the FSBEI CPE Russian Medical Academy of Continuous Professional Education of the Ministry of Health of the Russian Federation, Kazan, Russia

    2 shared publications

Latest Publications

  • Analysis of structure and dynamics of the anti-asthma drugs market in the Russian Federation: retail and hospital segments

    by G. S. Rozanova, I. V. Zhamborova, R. A. Bontsevich

    Anti-asthma drugs occupy an important place in the pharmacotherapy of chronic respiratory diseases, which determines the need for a comprehensive analysis of this segment of the pharmaceutical market. The purpose of this study was to identify quantitative and structural patterns in the development of the retail and hospital segments of the R03 drug market based on recent analytical data. The information base included analytical materials from RNC Pharma and public procurement data for 2025, processed using comparative, structural, and dynamic analysis methods, as well as elements of pharmacoeconomic evaluation. It was found that in 2025 both retail and hospital market segments demonstrated steady growth, accompanied by an increase in consumption volumes and value indicators. Strengthening of domestic manufacturers’ positions was identified, especially in the hospital segment, along with significant price differentiation between domestic and imported drugs. The retail market was characterized by a high level of concentration combined with a wide range of product offerings. Additionally, pronounced seasonality of demand and signs of transformation in consumer behavior were observed in early 2026. The obtained results indicate active import substitution processes and changes in consumption patterns, which require further study in terms of accessibility and effectiveness of pharmacotherapy.

  • Analysis of public procurement of josamycin for 2023–2024

    by I. V. Zhamborova, G. S. Rozanova

    This study is dedicated to a comprehensive analysis of public procurement of the antibiotic josamycin in Russia for the period 2023-2024. Transparency, openness, and competitiveness are generally accepted principles that must be strictly observed to achieve procurement efficiency, i.e. to save budget funds [1]. The research encompasses an assessment of procurement volume dynamics, regional distribution across federal districts, and changes in the consumption structure of various dosage forms of the drug. Particular attention is paid to the analysis of the market share occupied by the originator drug versus generic versions. The study reveals a sharp decline in procurement activity in 2024 and an absolute dominance of the originator brand. The work underscores the importance of the obtained results for planning budgetary expenditures and ensuring the accessibility of drug therapy within the healthcare system. The analysis utilized data from the Unified Information System of public procurement in the Russian Federation (EIS).

  • Analysis of public procurement for triple fixed-dose combinations in patients with COPD and bronchial asthma from 2020 to 2025

    by G. S. Rozanova, I. V. Zhamborova, R. A. Bontsevich

    The article examines the dynamics of the Russian budget market for triple fixeddose combinations used in the treatment of chronic obstructive pulmonary disease (COPD) and bronchial asthma (BA) over the period from 2020 to 2025. It describes the main combinations available on the market. The analysis demonstrates a steady increase in sales volume and gradual growth in the share of new drugs. The study highlights the significance of these medications as universal tools in treating broncho-obstructive syndromes and identifies prospects for further expansion of their employment in clinical practice.